Epidemiology of Neuroendocrine TumoursTaal B.G.a · Visser O.b
aDepartment of Gastroenterology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital and bComprehensive Cancer Centre Amsterdam, Amsterdam, The Netherlands
Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital
NL–1066 CX Amsterdam (The Netherlands)
Tel. +31 20 5122566, Fax +31 20 5122578, E-Mail firstname.lastname@example.org
Do you have an account?
Neuroendocrine tumours account for only 0.5% of all malignancies. The incidence is approximately 2/100,000 with a female preponderance under the age of 50 years due to appendiceal location. The main primary sites are the gastrointestinal tract (62–67%) and the lung (22–27%). Presentation with metastatic disease accounts for 12–22%. In the last decades, the incidence has been rising. This might be due to more awareness, improved diagnostic tools or a change in definition. Most neuroendocrine tumours are mainly sporadic, but association with the multiple endocrine neoplasia type 1 syndrome and clustering within families is known. Also an increased risk of secondary cancers has been reported, but numbers are small. The 5-year survival is mainly associated with stage: 93% in local disease, 74% in regional disease and 19% in metastatic disease. In metastatic disease, survival increased since 1992, when treatment with octreotide became largely available in the Netherlands.
© 2004 S. Karger AG, Basel
- Kulke MH, Mayer RJ: Carcinoid tumors. N Engl J Med 1999;40:858–868.
- Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH: Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996;14:1829–1838.
- Taal BG, Hoefnagel C, Boot H, Valdes Olmos R, Rutgers M: Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice. Ann Oncol 2000;11:1437–1443.
- Zuetenhorst JM, Bonfrer JM, Korse CM, Bakker R, van Tinteren H, Taal BG: Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003;97:1609–1615.
- Newton JN, Swerdlow AJ, dos Santos Silva IM, Vessey MP, Grahmae-Smith DG, Primatesta P, Reynolds DJM: The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer 1994;70:939–942.
- Westergaard T, Frisch M, Melbye M: Carcinoid tumors in Denmark 1978–1989 and the risk of subsequent cancers. A population-based study. Cancer 1995;76:106–109.
- Crocetti E, Buiatti E, Amorosi A: Epidemiology of carcinoid tumours in central Italy. Eur J Epidemiol 1997;13:357–359.
- Levi F, Te VC, Randimbison L, Rindi G, La Vecchia C: Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974–1997. Br J Cancer 2000;83:952–955.
- Quaedvlieg PF, Visser O, Lamers CB, Janssen-Heijen ML, Taal BG: Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2,391 patients. Ann Oncol 2001;12:1295–1300.
- Hemminki K, Li X: Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden. Cancer 2001;92:2204–2210.
- Modlin IM, Lye KD, Kidd M: A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003;97:934–959.
- Tomassetti P, Migliori M, Lalli S, Campana D, Tomassetti V, Corinaldesi R: Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol 2001;12(suppl 2):S95–S99.
- Levi F, Randimbison L, Franceschi S, La Vecchia C: Descriptive epidemiology of malignant carcinoids in the Swiss Canton of Vaud. Int J Cancer 1993;53:1036–1037.
- Hemminki K, Li X: Familial carcinoid tumors and subsequent cancers: A nation-wide epidemiologic study from Sweden. Int J Cancer 2001;94:444–448.
- Kaerlev L, Teglbjaerg PS, Sabroe S, Kolstad HA, Ahrens W, Eriksson M, et al: Occupational risk factors for small bowel carcinoid tumor: A European population-based case-control study. J Occup Environ Med 2002;44:516–522.
van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R, Aleman BM: Long-term risk of second malignancy in survivors of Hodgkin’s disease treated during adolescence or young adulthood. J Clin Oncol 2000;10:2186–2187.
- Skuladottir H, Hirsch FR, Hansen HH, Olsen JH: Pulmonary neuroendocrine tumors: Incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 2002;37:127–135.